HBOT for Ulcerative Colitis: Early Trials and an Ongoing UCLA Study
Small trials suggest HBOT may help hospitalized ulcerative-colitis flares, and a larger UCLA trial is underway. Strictly experimental, and only as an adjunct.
The rationale
Ulcerative colitis is a chronic inflammatory bowel disease, and one feature of the inflamed colon is low tissue oxygen. That observation is the rationale for testing hyperbaric oxygen therapy, which raises tissue oxygen levels, as a possible add-on treatment during acute flares. The idea is mechanistically plausible - more available oxygen in poorly oxygenated, inflamed tissue - but plausibility is not proof, and the history of medicine is full of plausible ideas that did not pan out in trials.
It is important to be clear from the outset that this is an experimental, adjunctive idea under investigation, not established therapy and not a replacement for standard treatment. Standard care for ulcerative colitis - including steroids, biologics and other medicines - remains the backbone; HBOT is being tested alongside it, not instead of it.
What small trials have suggested
According to the UCLA study description, two small prospective randomised controlled trials have reported that delivering HBOT to ulcerative-colitis patients hospitalised for acute moderate-to-severe flares improved remission rates and helped some patients avoid in-hospital escalation to biologics, other advanced medications, or colectomy.
These are encouraging early signals, but they come from small studies and describe a specific, hospitalised, acute-flare population - not routine outpatient management. Small early trials can point in a promising direction and still not hold up when tested at scale. Avoiding escalation to biologics or surgery is a meaningful goal for hospitalised patients, which is exactly why the early results drew attention and why they need confirming.
The ongoing HBOT-UC trial
To test the idea more rigorously, UCLA is running the HBOT-UC trial: a prospective, double-masked, multicentre, sham-controlled study that plans to randomise 126 hospitalised patients one-to-one to either HBOT plus steroids or sham hyperbaric air plus steroids. The intervention runs over five days, followed by a 12-month observational follow-up.
The primary outcome is a clinical response by day five - complete resolution of rectal bleeding and improved stool frequency without needing in-hospital biologics, advanced medications, or colectomy. The longer follow-up is designed to say something about how durable any early response turns out to be, and the study is also set up to examine the immune and microbial mechanisms behind any treatment response.
How to read this honestly
The trial's design - blinding, a sham comparator and a multicentre setting - is exactly what is needed to move beyond preliminary signals. Until it and similar studies report, HBOT for ulcerative colitis remains investigational and should be framed as an adjunct under study, not a substitute for standard care. Framing matters here: presenting an investigational adjunct as an established option would get ahead of the evidence. For general context on the chambers used in clinical protocols like this, see our overview at HBOT chambers.
Ulcerative colitis is managed by specialists for good reason. Anyone curious about HBOT for inflammatory bowel disease should raise it with their gastroenterologist, ideally in the context of a properly supervised clinical trial.